Safety Study of APD-791 With Aspirin and/or Clopidogrel

NCT ID: NCT02034292

Last Updated: 2019-02-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2014-03-31

Brief Summary

Evaluating safety and PK parameter of APD-791 when co-administered with aspirin and clopidogrel.

Conditions

Acute Coronary Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SCREENING
• Blinding Strategy: QUADRUPLE

Study Groups

10mg MD

APD791 10mg Multiple dose and

Group Type: EXPERIMENTAL

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

20mg MD

APD791 20mg Multiple dose

Group Type: EXPERIMENTAL

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

40mg MD

APD791 40mg Multiple dose

Group Type: EXPERIMENTAL

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

60mg MD

APD791 60mg Multiple dose

Group Type: EXPERIMENTAL

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

Placebo MD

Placebo for Multiple dose group

Group Type: PLACEBO_COMPARATOR

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

120mg SD

APD791 120mg Single dose

Group Type: EXPERIMENTAL

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

240mg SD

APD791 240mg Single dose

Group Type: EXPERIMENTAL

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

320mg SD

APD791 320mg Single dose

Group Type: EXPERIMENTAL

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

Placebo SD

Placebo for Single dose

Group Type: PLACEBO_COMPARATOR

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Interventions

Clopidogrel

Intervention Type: DRUG

Aspirin

Intervention Type: DRUG

APD791

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. a healthy adult between 20 and 45 years old at the time of visit for screening

2. a person who is able to give written consent

3. a person between 50 and 85 kg at the time of visit for screening

4. a woman who is negative on a serum hCG test at the time of visit and the day before a trial, and who is not nursing

5. a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal

6. a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm

7. a person more than hemoglobin 12 g/dL at the time of screening (a woman more than hemoglobin 11 g/dL)

8. a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator

9. a person who voluntarily decides to participate in this clinical trial and gives written consent on strict clinical trial compliance

10. a person whose blood can be collected during a study period with visit for monitoring

Exclusion Criteria

1. a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening

2. a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug

3. a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening

4. a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening

5. a person with the medical history of epilepsy or convulsion

6. a person with the medical history of internal organ transplant

7. a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period

8. a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator's decision

9. a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction

10. a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening

11. a person with the medical history of alcohol abuse within two years from the time of visit for screening

12. a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening

13. a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening

14. a person taking other clinical trial drugs within 90 days from the time of visit for screening

15. a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening

16. a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test)

17. a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL)

18. a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator's medical decision at the time of visit for screening

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Asan Medical Center

OTHER

Sponsor Role: collaborator

IlDong Pharmaceutical Co Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

ID-TG1C-1301

Identifier Type: -

Identifier Source: org_study_id